Epizyme

Epizyme, Inc. was a Cambridge, Massachusetts biopharmaceutical company developing epigenetic therapies for cancer and other diseases. Its lead product, TAZVERIK (tazemetostat), is an oral EZH2 inhibitor approved by the FDA for epithelioid sarcoma and relapsed/refractory follicular lymphoma. Epizyme was acquired by Ipsen in 2022. It was added to the API Evangelist network as a stub via the kleiner-perkins venture portfolio; the company operates no public developer program, API, or documentation surface, and its former corporate website (epizyme.com) is no longer serving a web presence though the domain remains registered and mail-active.

Epizyme is profiled on the APIs.io network. Tagged areas include Company, Healthcare, Biotechnology, Pharmaceuticals, and Oncology.

🌐 Visit website 📡 Source on GitHub
7.7/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-07-27 · rubric v0.5
0 APIs
CompanyHealthcareBiotechnologyPharmaceuticalsOncologyEpigenetics

Kin Score

Kin Score Kin Score How this is scored →
scored 2026-07-27 · rubric v0.5
Composite quality — 7.7/100 · minimal
Contract Quality 0.0 / 25
Developer Ergonomics 0.0 / 20
Commercial Clarity 0.0 / 20
Operational Transparency 0.0 / 13
Governance 0.0 / 12
Discoverability 6.8 / 10
Agent readiness — 0/100 · human only
Machine-Readable Contract 0 / 18
Agentic Access Contract 0 / 15
MCP Server 0 / 12
Machine-Readable Auth 0 / 10
Idempotency 0 / 9
Stable Error Semantics 0 / 8
Request/Response Examples 0 / 7
Rate-Limit Signaling 0 / 7
Typed Event Surface 0 / 6
Agent Skills 0 / 5
Well-Known Catalog 0 / 4
Consent & Bot Identity 0 / 3
Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/epizyme: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Security Posture 1

Authentication, domain security, vulnerability disclosure, and trust-center signals.

Epizyme Domain Security

DMARC

SECURITY

Resources

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity
DomainSecurity

Company 1

The organization behind the API

Website
Website

Source (apis.yml)

apis.yml Raw ↑ 
aid: epizyme
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/epizyme.png
name: Epizyme
description: Epizyme, Inc. was a Cambridge, Massachusetts biopharmaceutical company developing epigenetic therapies for cancer
  and other diseases. Its lead product, TAZVERIK (tazemetostat), is an oral EZH2 inhibitor approved by the FDA for epithelioid
  sarcoma and relapsed/refractory follicular lymphoma. Epizyme was acquired by Ipsen in 2022. It was added to the API Evangelist
  network as a stub via the kleiner-perkins venture portfolio; the company operates no public developer program, API, or documentation
  surface, and its former corporate website (epizyme.com) is no longer serving a web presence though the domain remains registered
  and mail-active.
url: https://raw.githubusercontent.com/api-evangelist/epizyme/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- kleiner-perkins
x-tier: stub
x-tier-reason: portfolio-lead
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-19'
tags:
- Company
- Healthcare
- Biotechnology
- Pharmaceuticals
- Oncology
- Epigenetics
apis: []
common:
- type: Website
  url: https://www.epizyme.com
- type: DomainSecurity
  url: security/epizyme-domain-security.yml
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
x-enrichment:
  date: '2026-07-19'
  status: backfilled
  pass: local-v1
  note: backfilled from .gitignore signal + verified work evidence